Xylazine in Canada’s Drug Supply: What the Health Data Actually Shows
This article discusses drug contamination and overdose risk. If you or someone you know is struggling with substance use, Health Canada’s Get Help With Substance Use page lists free, confidential support across every province.
What xylazine is, and why it’s showing up in the illicit drug supply
Xylazine is a veterinary sedative approved only for animal use in Canada — it has no approved human application, and no antidote reverses it. It has increasingly been found mixed into the illicit fentanyl supply, first flagged in Canada by the Canadian Centre on Substance Use and Addiction (CCENDU) in a 2022 alert and tracked since through toxicology testing at supervised consumption sites and coroners’ offices.
Why it makes overdoses harder to reverse
Naloxone reverses opioid overdoses by blocking opioid receptors — but xylazine isn’t an opioid, so naloxone does nothing for the sedation and respiratory depression it causes on its own. In a fentanyl-xylazine mixture, naloxone still reverses the opioid component, but a person can remain unresponsive and at risk of respiratory failure even after naloxone is administered — which is exactly why harm-reduction groups have pushed to update public overdose-response training rather than relying on outdated single-drug assumptions, as reported by CBC News.
The wound risk is separate from the overdose risk
Beyond sedation, repeated xylazine exposure is associated with severe skin wounds and tissue necrosis at and away from injection sites — a distinct harm profile from opioids alone, and one that’s driven emergency-department visits in US cities where xylazine contamination arrived earlier and more heavily than in most of Canada. Health Canada’s own spotlight report on the emergence of xylazine in Canada documents this pattern and Canada’s comparatively earlier-stage exposure as of its publication.
What public health authorities are recommending
Harm-reduction guidance from groups like CATIE emphasizes drug-checking services (available at supervised consumption sites in most major Canadian cities) so people can know what’s actually in a substance before using it, wound care education for people who use drugs regularly, and continued naloxone carrying and training — since most street supply remains fentanyl-based with xylazine as an additive, not a replacement, meaning naloxone still matters even where xylazine is present.
The bottom line
Xylazine is not intended for, or safe for, human use under any circumstance — it carries risks (unreversible sedation, severe wounds) that are additive to, not replacements for, the risks of the opioids it’s typically found alongside. Anyone using drugs from the unregulated supply in Canada should use drug-checking services where available and never use alone.
Practical harm-reduction steps that make a measurable difference
Using a spotter (in person or via a virtual overdose-monitoring service, several of which now operate by phone across Canada), carrying naloxone even though it doesn’t reverse xylazine’s sedation directly, and using new or sterile equipment for every use to reduce wound risk at injection sites are the concrete steps harm-reduction organizations recommend right now, given how widespread fentanyl-xylazine mixing has become in several provinces’ supply.
Wound care shouldn’t be delayed out of stigma
Because xylazine-associated wounds can worsen quickly and are a distinct medical issue from overdose, seeking wound care early — at a supervised consumption site, a nurse-led clinic, or a hospital — matters even when someone isn’t ready to discuss their drug use more broadly. Several Canadian harm-reduction sites now offer wound care specifically without requiring disclosure of full substance-use history, precisely to lower that barrier.
Sources & Further Reading
- Health Canada — Get Help With Substance Use
- CBC News — tranq/xylazine coverage
- Health Canada — Spotlight: The Emergence of Xylazine in Canada (PDF)
- CATIE — Update on xylazine in the unregulated drug supply
